Survival Curves

Breast Cancer


These results published in the Journal of Clinical Oncology reveal a statistically significant correlation between drug sensitivity and time to progression.

This seminal paper reintroduced platinum-based chemotherapy for the treatment of advanced breast cancer. Related combinations continue to provide significant improvement in advanced breast cancer survival.

Ovarian Cancer

This analysis published in Gynecologic Oncology represents a prospective correlation between drug sensitivity to the combination of cisplatin and gemcitabine in patients with a mixture of platinum-sensitive and platinum-resistant disease.


Results reveal a statistically significant correlation between drug sensitivity and time to progression.  In addition, this publication revealed a statistically significant correlation between drug sensitivity and clinical response, as well as drug sensitivity and overall survival.


This drug combination, developed by Rational Therapeutics (now Nagourney Cancer Institute), received FDA approval in July 2006 predicated upon this landmark study and the subsequent GOG clinical trial written by Dr. Nagourney (Gyn Oncol, 2006).



This analysis reveals a statistically significant survival advantage for patients receiving assay sensitive therapy in advanced metastatic melanoma.

Despite melanoma’s drug-refractory (resistant) nature, novel drug combinations provided durable responses in a high percentage of patients.

Small Cell Lung Cancer

This analysis in small cell lung cancer, published by investigators at the National Cancer Institute, utilizing laboratory techniques developed and applied here at Rational Therapeutics (now Nagourney Cancer Institute), correlates survival with the use of the “in vitro best regimen” (IVBR).

With a 39 percent durable complete remission rate for patients receiving assay “sensitive” therapy, this remains one of the best outcomes in this lethal disease ever reported.

Chronic Lymphocytic Leukemia (CLL)

CLL, the most common adult leukemia, is responsive to chemotherapy, but rarely curable.

This analysis identifies a subset of patients with resistant disease who suffer early relapse and death.

By identifying these patients at initial diagnosis, more effective therapies could be administered to provide more durable clinical response.

Stack of Magazines

Published Papers

Test Tubes

Assay-Directed Therapy




  • Facebook
  • YouTube
  • Instagram

Nagourney Cancer Insitute is managed by Rational Therapeutics, LLC.  EVA-PCD, Target Rx, and Translational Rx are registered trademarks of Rational Therapeutics.

2019 Nagourney Cancer Institute.  750 E. 29th Street, Long Beach, CA 90806   (800) 542-4357   All rights reserved.